All posts by admin

14Mar/14

FDA Approves Merck's NOXAFIL® (posaconazole) Injection (18 mg/mL) for … – EIN News (press release)

FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for
EIN News (press release)
The administration of NOXAFIL with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments 

and more »

14Mar/14

FDA Approves Merck's NOXAFIL(R) (posaconazole) Injection (18 mg/mL) for … – Wall Street Journal

FDA Approves Merck’s NOXAFIL(R) (posaconazole) Injection (18 mg/mL) for
Wall Street Journal
The administration of NOXAFIL with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments 

and more »

14Mar/14

FDA Approves Merck's NOXAFIL® (posaconazole) Injection (18 mg/mL) for … – MarketWatch


Drug Discovery & Development

FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for
MarketWatch
The administration of NOXAFIL with sirolimus, pimozide, quinidine,atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments and
FDA Approves Merck’s NOXAFIL(R) (posaconazole) Injection (18 mg/mL) for Wall Street Journal

all 10 news articles »

14Mar/14

FDA Approves Merck's NOXAFIL ® (posaconazole) Injection (18 mg/mL) for … – Business Wire (press release)

FDA Approves Merck’s NOXAFIL ® (posaconazole) Injection (18 mg/mL) for
Business Wire (press release)
The administration of NOXAFIL with sirolimus, pimozide, quinidine, atorvastatin, lovastatin, simvastatin and ergot alkaloids must be avoided. When administered with NOXAFIL, some drugs such as cyclosporine and tacrolimus required dosage adjustments 

14Mar/14

Bladder Cancer Patient on Everolimus Has Complete Response – Cancer Network


Cancer Network

Bladder Cancer Patient on Everolimus Has Complete Response
Cancer Network
In a phase I trial, a bladder cancer patient has had a 14-month complete response with the combination of the mTOR inhibitor everolimus and pazopanib, a selective multi-targeted receptor tyrosine kinase inhibitor that targets angiogenesis, including
Patient with advanced bladder cancer shows complete response to everolimus News-Medical.net
Exceptional Responder Provides Treatment Clues in Bladder CancerOncLive
Genomic testing links ‘exceptional’ drug response to rare mutations in bladder EurekAlert (press release)

all 11 news articles »